At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DVA DaVita HealthCare Partners
Post-Mkt 04-06 16:58:26 EDT
150.12
+4.54
+3.12%
盘后150.12
+0.000.00%
16:15 EDT
High150.22Low144.76Vol640.76K
Open144.76D1 Closing145.58Amplitude3.75%
Mkt Cap10.03BTradable Cap5.29BTotal Shares66.80M
T/O95.68MT/O Rate1.82%Tradable Shares35.22M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

DaVita Inc. Stock Advances 3.1%, Outperforms Peers
Dow Jones  ·  24 minutes ago
DaVita Inc. Stock Advances 3.1%, Outperforms Peers
Is DaVita’s (DVA) AI-Driven Home Dialysis Push Redefining Its Long-Term Competitive Moat?
Simply Wall St.  ·  04-04 19:23
Is DaVita’s (DVA) AI-Driven Home Dialysis Push Redefining Its Long-Term Competitive Moat?
DaVita Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  03-26
DaVita Inc. Stock Outperforms Competitors On Strong Trading Day
AllianceBernstein Global High Income Fund Inc. Publishes Report; NAV $11.42
Reuters  ·  03-24
AllianceBernstein Global High Income Fund Inc. Publishes Report; NAV $11.42
DaVita reports 9% Total Quality Score improvement and more than USD 200 million in CKCC shared savings
Reuters  ·  03-19
DaVita reports 9% Total Quality Score improvement and more than USD 200 million in CKCC shared savings
DaVita Mixes Strong Value Signals With Distress Score And Insider Selling
Simply Wall St.  ·  03-18
DaVita Mixes Strong Value Signals With Distress Score And Insider Selling
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
prnewswire  ·  03-17
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing
Reuters  ·  03-17
BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing
R1 Therapeutics: Proceeds From Series a Financing to Fund R1's Global Development Program of AP306
THOMSON REUTERS  ·  03-17
R1 Therapeutics: Proceeds From Series a Financing to Fund R1's Global Development Program of AP306
R1 Therapeutics: Financing Was Co-Led by Abingworth, F-Prime, & DaVita Venture Group, With Participation From Curie.bio, Symbiosis, & U.S. Renal Care
THOMSON REUTERS  ·  03-17
R1 Therapeutics: Financing Was Co-Led by Abingworth, F-Prime, & DaVita Venture Group, With Participation From Curie.bio, Symbiosis, & U.S. Renal Care
R1 Therapeutics launches with $78 million funding round, secures kidney disorder treatment license
Reuters  ·  03-17
R1 Therapeutics launches with $78 million funding round, secures kidney disorder treatment license
DaVita Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  03-13
DaVita Inc. Stock Outperforms Competitors Despite Losses On The Day
DaVita Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  03-05
DaVita Inc. Stock Outperforms Competitors On Strong Trading Day
DaVita Inc. Stock Underperforms Monday When Compared To Competitors
Dow Jones  ·  03-03
DaVita Inc. Stock Underperforms Monday When Compared To Competitors
DaVita Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  02-28
DaVita Inc. Stock Outperforms Competitors On Strong Trading Day
DaVita CFO Joel Ackerman and IR VP Nic Eliason to Join Fireside Chat at TD Cowen 46th Annual Health Care Conference
Reuters  ·  02-25
DaVita CFO Joel Ackerman and IR VP Nic Eliason to Join Fireside Chat at TD Cowen 46th Annual Health Care Conference
Three hurt working on Exxon Beaumont, Texas small CDU, sources say
Reuters  ·  02-14
Three hurt working on Exxon Beaumont, Texas small CDU, sources say
20 Stocks of Companies That Delivered a Double Dose of Growth This Earnings Season
Dow Jones  ·  02-12
20 Stocks of Companies That Delivered a Double Dose of Growth This Earnings Season
20 stocks of companies that delivered a double dose of growth this earnings season
Dow Jones  ·  02-12
20 stocks of companies that delivered a double dose of growth this earnings season
DaVita posts FY debt expense of USD 580 million, up 23.4%
Reuters  ·  02-12
DaVita posts FY debt expense of USD 580 million, up 23.4%
No data available

Introduction

Company Name.
DaVita HealthCare Partners
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Issue price:
--